What is plasmalogen
Plasmalogen It is usually calledplasmalogenin Chinese, and its Japanese name is プラズマローゲン. It is not a single molecule, but an entire class of ether phospholipids and membrane phospholipids that naturally exist in large quantities in the human body. Commercial supplements are also divided by sources such as scallops, sea squirts, and chicken breast. The composition of fatty chains and fatty acids in different raw materials is not exactly the same, so one cannot judge whether products are equivalent based solely on the name and milligram amount.
Plasmalogen has already accumulated some human randomized, double-blind, placebo-controlled studies, with a number of studies exceeding that of many common brain health ingredients. Some small studies, cognitive subitems, and subgroup analyses have shown that memory, spatial orientation, or sustained task performance may improve; however, the largest trial to date with 328 participants did not show significant superiority over placebo on the predefined primary endpoint for all participants.
Structure and distribution in the human body
Special vinyl ether bond
Plasmalogens belong to glycerophospholipids. In ordinary glycerophospholipids, the sn-1 position of the glycerol backbone is usually connected to a fatty chain via an ester bond, whereas the sn-1 position of plasmalogens has a specialVinyl ether bond; the sn-2 position usually connects polyunsaturated fatty acids such as DHA and arachidonic acid, and the sn-3 position connects ethanolamine or choline.
- PlsEtn：Ethanolamine plasmalogen, especially abundant in brain tissue
- PlsCho：Choline plasmalogen, is another main type of plasmalogen in the human body
- Difference from DHA:Plasmalogen is not another name for DHA, but a special membrane phospholipid structure that can carry fatty acids such as DHA and AA
Natural Components in Neuronal Cell Membranes, Synapses, and Myelin
Plasmalogens are naturally an important component of human cell membranes and are closely related to neuronal cell membranes, synaptic membranes, and myelin sheaths. In the brain, ethanolamine plasmalogens are predominant. The human body can also synthesize this type of lipid: the synthesis process begins in the peroxisomes and then moves to the endoplasmic reticulum to complete the subsequent steps. Therefore, it is more of a structural lipid of brain cell membranes rather than a component that can rapidly stimulate the nervous system.
Why They Are Used in Cognitive and Alzheimer's Disease Research
In autopsy brain tissue and some blood studies of Alzheimer's disease patients, decreased levels of certain ethanolamine plasmalogens are often observed. This phenomenon may be the result of neurodegenerative changes, or it may in turn affect neural membranes, synapses, antioxidant capacity, and signal transduction. It is not yet clear how much each of these two directions contributes to the progression of the disease in humans.
Therefore, lower levels in patients can only indicate an association with the disease and cannot directly prove that oral supplementation can treat the disease. Moving from correlation to therapeutic effect requires support from human randomized trials, disease biomarkers, and long-term clinical outcomes, and the existing evidence has not yet reached this point.
Potential physiological functions
- Maintaining cell membrane structure:Involved in the composition of nerve membranes, synaptic membranes, and myelin, and affects the physical properties of membranes
- Supporting synaptic function:Neurotransmitter release, synapse formation, and membrane fusion all depend on an appropriate membrane lipid environment
- Carrying polyunsaturated fatty acids:The sn-2 position can bind DHA, arachidonic acid, and other long-chain fatty acids
- Buffering oxidative stress:Ether bonds are more sensitive to oxidation and may act as preferentially oxidized buffer structures within the membrane
- Involved in cell signaling:Cellular and animal studies involve neuro-survival and plasticity-related pathways such as ERK, Akt, CREB, and BDNF
How it is absorbed after ingestion
It can be absorbed, but the intact molecule does not directly reach the brain
Animal digestion and absorption experiments show that plasmalogens in the diet can be absorbed by the intestines and alter the composition of related lipids in plasma and red blood cell membranes. During digestion, hydrolysis, remodeling, and re-esterification occur, so the plasmalogens that later appear in the blood are not necessarily identical to the original food molecules. This means that oral supplementation may provide intact lipids, metabolic products, or raw materials needed for resynthesis, but it should not be simply understood that every ingested molecule directly enters brain cell membranes.
The blood-brain barrier remains an unresolved issue
Currently, there is no reliable human data to indicate how much intact plasmalogen crosses the blood-brain barrier into the brain after a daily intake of 1 milligram. Mouse studies have found that after oral administration, hippocampus-related plasmalogen levels and learning and memory performance can improve, but there may be two mechanisms: One is that exogenous molecules or their metabolites enter the brain, and the other is that peripheral metabolism, inflammation, or immune changes indirectly affect neural function. The two cannot currently be completely separated.
Most important human trial: 328 people over 24 weeks
A multicenter, randomized, double-blind, placebo-controlled study published in 2017 is one of the highest-weighted trials in evaluating plasmalogen. The study included a total of 328 participants aged 60–85, including people with mild cognitive impairment and mild Alzheimer's disease. The intervention group took 1 mg of purified plasmalogen from scallops dailyfor 24 weeks, and eventually 276 people completed the study, including 140 in the plasmalogen group and 136 in the placebo group.
There was no significant advantage in the overall primary endpoint
The study used the MMSE-J as the primary endpoint, while also evaluating WMS-R memory tests, depression scores, and blood plasmalogen levels. When analyzed according to the intention-to-treat principle, combining subjects with mild cognitive impairment and mild Alzheimer's disease, the plasmalogen group did not show a significant advantage between groups for either primary or secondary cognitive endpoints. Therefore, this study cannot be summarized as having proven that plasmalogen improves Alzheimer's disease.
The positive results mainly came from subgroups
When analyzing the mild Alzheimer's disease population separately, the plasmalogen group showed an improvement in WMS-R memory function, but the difference between the entire mild Alzheimer's disease group and the placebo group was about p=0.067, not reaching the commonly used p<0.05 standard. Further stratification showed that the intergroup difference for female patients with mild Alzheimer's disease was p=0.017, and for patients under 77 years old it was p=0.029.
These results suggest that women or younger patients with mild symptoms may be more likely to benefit, but the strength of evidence is lower than that of the prespecified primary endpoints for the overall population. After the data are divided into multiple subgroups, such as disease type, sex, and age, the probability of finding significant results by chance increases, so these findings are better suited as hypotheses for further research rather than confirmed conclusions about the applicable population.
Further analysis of 178 participants with mild cognitive impairment
In 2018, researchers conducted a separate analysis on 178 subjects with mild cognitive impairment from the aforementioned large trial, including 90 in the plasmalogen group and 88 in the placebo group, with an average age of about 76 years, and the dose remained 1 mg per day for 24 weeks.
The total MMSE-J score improved within the plasmalogen group, but there was no significant difference in total score changes compared to the placebo group. Therefore, the existing data do not support that plasmalogen can comprehensively improve overall cognition in patients with mild cognitive impairment.
A significant signal appears in the location orientation subitem
The MMSE orientation to place item is used to determine whether the subject can correctly identify locations such as the city, hospital, or building. In this sub-item, the plasmalogen group showed improvement, while the placebo group did not show the same change, with a between-group p-value of 0.003; the results remained statistically significant after multiple comparison corrections.
Most other MMSE subitems, including other orientation, registration, attention, and language, did not consistently show an advantage. The safest interpretation of this analysis is that there may be a signal of effect in spatial or place orientation ability, rather than plasmalogen being able to comprehensively improve or treat mild cognitive impairment.
Study on healthy adults with mild forgetfulness
A 2020 randomized, double-blind, placebo-controlled trial used plasmalogen derived from sea squirts, involving 49 healthy Japanese adults who felt they had mild forgetfulness, with an average age of about 46 years. The plasmalogen group included 25 people and the placebo group 24 people, taking 1 milligram daily for 12 weeks.
The study used the Cognitrax cognitive test, with the main positive indicator being the composite memory score consisting of verbal memory and visual memory. Compared with the placebo, the plasmalogen group showed better changes in composite memory at weeks 8 and 12; at week 12, the plasmalogen group improved by about 6.7 ± 17.5 points relative to their baseline.
The value of this study lies in the fact that the subjects were not dementia patients, indicating that the research scope is not limited to disease populations. However, the total sample size was only 49 people, and the participating team included both food and clinical research institutions. At present, multiple large independent teams have not yet replicated this result.
Research Clues from Chicken Breast
There is also research in Japan on plasmalogen sourced from chicken breast. In 2019, a placebo-controlled, randomized, double-blind, parallel-group trial was published targeting healthy adults, with the study focusing on brain function. Related human trials often use a dose of 0.5 to 1 milligram per day. Therefore, the fact that Japanese commercial products only indicate 0.5 to 1 milligram per day is not necessarily a printing error, but rather follows the common dosage range used in such food studies.
The sn-1 fatty chains, sn-2 polyunsaturated fatty acids, and the proportions of PlsEtn and PlsCho may vary among products from different sources. Results from studies on scallop-derived products cannot be fully applied to chicken breast or sea squirt-derived products; similarly, a positive effect from 1 mg per day of a certain sea squirt-derived raw material does not mean that products from all sources and purities will have the same effect.
Study on mood and concentration of young male athletes
A 2022 study included 40 male college athletes aged 18–22, with 20 participants in the plasmalogen group and 20 in the placebo group. The subjects took 2 mg of scallop-derived plasmalogen daily for 4 weeks. The primary observation was the POMS mood scale, while also testing sleep, mental concentration, athletic performance, and multiple blood indicators.
Some mood subscales improved, but the total score was not significant
After 4 weeks, the between-group difference in the Anger-Hostility subscale was p=0.003, and the Fatigue-Inertia subscale was p=0.005. However, the between-group difference in the overall POMS total mood disturbance score was p=0.07, which did not reach the conventional threshold for statistical significance. Therefore, this study supports that there are signals of improvement in two specific subscales, but it cannot be concluded that overall mood has clearly improved.
Preliminary signs of sustained operational capability appear
The study also used the Uchida-Kraepelin performance test, which requires subjects to continuously perform simple calculations, in order to observe changes in performance during sustained attention and long-duration tasks. The plasmalogen group performed better in the later minutes of the task, suggesting that it may help maintain attentional states during continuous tasks. Since the sample only included 40 individuals, all young male athletes, and the intervention lasted only 4 weeks, this still constitutes preliminary evidence.
Biomarkers did not provide clear mechanistic support
In the same trial, there were no significant inter-group changes in plasma and red blood cell plasmalogens, blood BDNF, or the oxidative stress marker 8-OHdG. The appearance of signals on behavioral scales without corresponding changes in related biological markers indicates that the specific pathways of action in the human body remain unclear.
How to view human randomized trials together
| Population and design | Dose and duration | Main results |
|---|---|---|
| 328 subjects with mild cognitive impairment or mild Alzheimer's disease | Scallop-derived 1 mg/day, 24 weeks | No significant advantage in all primary and secondary cognitive endpoints; signals appeared in female and mild patients under 77 years old subgroups |
| Reanalysis of 178 mild cognitive impairment subjects | 1 mg/day, 24 weeks | No significant group difference in total MMSE score; spatial orientation subscore p=0.003 |
| 49 healthy adults with mild forgetfulness | Sea squirt-derived 1 mg/day, 12 weeks | At weeks 8 and 12, overall memory changes were better than placebo, but the sample size was small |
| 40 young male university athletes | Scallop-derived 2 mg/day, 4 weeks | Some mood subscales and sustained task performance improved; overall mood primary endpoint was not significant |
These trials are not completely without effect, nor have they formed a stable, comprehensive picture of cognitive improvement. The more positive results are mainly concentrated on language and visual associative memory, spatial orientation, and performance on certain sustained tasks, and they are also more dependent on specific subtests, specific populations, or post hoc subgroups. Evidence regarding overall cognition, disease treatment, and long-term prevention is significantly weaker.
Why doses as low as 1 milligram are still being studied
From the perspective of traditional nutritional supplementation, 1 milligram per day is indeed very little, far below the dose of many common phospholipid supplements. Therefore, the research team suggested that the role of plasmalogens may not be merely to massively fill cell membranes as membrane substrates, but may also influence cellular receptors and pathways such as ERK, Akt, and GPCR at low concentrations as signaling lipids.
This explanation currently mainly comes from cell and animal studies. In humans, a complete causal chain from ingesting 1 mg daily, acting on a specific brain receptor, to memory improvement has not yet been confirmed. Evidence for low doses does not mean that higher doses have stronger effects, and existing human trials have not established a dose-response relationship between 1 mg, 10 mg, and 100 mg.
Mechanisms of action in cell and animal studies
ERK, Akt, and neuronal survival
Cell studies in 2013 found that plasmalogen can activate Akt and ERK survival signals and reduce neuronal cell death under experimental conditions. These two pathways are involved in neuron survival, growth, plasticity, and synaptic function, providing a mechanistic basis for plasmalogen not only as a passive membrane material. Signal changes in cell cultures cannot be directly equated with cognitive effects after ingestion in humans.
BDNF, Neurogenesis, and Learning and Memory
A 2022 mouse study found that after oral plasmalogen, hippocampal BDNF increased, accompanied by neurogenesis and improvements in learning and memory. The proposed candidate pathway is that plasmalogen affects ERK, Akt, and CREB, further promoting Bdnf transcription and BDNF expression, ultimately acting on synaptic plasticity and neurogenesis.
Human results did not fully replicate this mechanism. In the aforementioned trial with young athletes measuring blood BDNF, there was no significant difference between the plasmalogen group and the placebo group. The increase in BDNF in the mouse brain can only serve as a potential explanation and cannot be directly inferred that BDNF in humans will necessarily increase after ingestion.
Microglia and neuroinflammation
In a lipopolysaccharide-induced neuroinflammation mouse model, oral plasmalogen can reduce microglial activation and improve memory impairment. The possible pathway is that excessive microglial activation decreases, neuroinflammation is subsequently alleviated, the synaptic environment is improved, and ultimately memory performance is affected. This chain is still mainly supported by animal models.
Amyloid-related findings
In some animal models, a reduction in Aβ accumulation or amyloid-related pathological changes has also been observed, which is one of the reasons plasmalogen is often promoted for Alzheimer's disease prevention. However, existing human randomized trials have not demonstrated a decrease in amyloid PET signals, improvement in cerebrospinal fluid Aβ, or improvement in phosphorylated tau, nor have they demonstrated a reduction in the incidence of Alzheimer's disease or the conversion rate from mild cognitive impairment to dementia.
Evaluation of evidence for different cognitive functions
| Cognitive or health direction | Current evidence evaluation |
|---|---|
| Language and visual combined memory | ★★★☆☆～★★★★☆ |
| Verbal memory | ★★★☆☆ |
| Spatial and place orientation | ★★★☆☆～★★★★☆ |
| General memory retrieval | ★★★☆☆ |
| Long-term sustained concentration | ★★☆☆☆～★★★☆☆ |
| Reaction and processing speed | ★★☆☆☆～★★★☆☆ |
| Overall cognitive ability | ★★☆☆☆～★★★☆☆ |
| Learning ability of healthy young people | ★★☆☆☆ |
| Potential help for people with mild cognitive impairment | ★★☆☆☆～★★★☆☆ |
| Treatment of mild cognitive impairment | ★★☆☆☆ |
| Treatment of Alzheimer's disease | ★★☆☆☆ |
| Prevention of Alzheimer's disease | ★☆☆☆☆ |
Currently, there is a lack of high-quality, independent large-scale meta-analyses to provide a stable unified effect size. Different trials used MMSE, WMS-R, Cognitrax, and the Uchida-Kraepelin test, with significant differences in indicators, making it temporarily impossible to reliably convert to a unified average improvement magnitude. A more realistic expectation is that certain cognitive domains in some individuals may show slight improvement, rather than a noticeable enhancement of overall memory or learning ability in the short term.
Evidence for treating mild cognitive impairment or Alzheimer's disease
Cannot be considered as a treatment for mild cognitive impairment
Among 178 people analyzed, there was no significant group advantage in the total MMSE score; only the orientation-to-place subscore showed a relatively strong signal. This suggests that some specific cognitive domains may benefit, but it is insufficient to conclude that the treatment is effective for mild cognitive impairment. For those who have already experienced cognitive decline, it is more important to conduct a formal assessment of reversible causes, control cardiovascular and metabolic risks, and follow treatment as advised by a doctor.
Cannot be used as a treatment or preventive measure for Alzheimer's disease
In a trial of 328 people, the primary analysis for mild cognitive impairment and the overall mild Alzheimer's disease group was negative; the between-group difference in WMS-R for the mild Alzheimer's disease group was about p=0.067, with only the further subdivided female and under-77 subgroups reaching p<0.05. This is still far from formally establishing the effectiveness of Alzheimer's treatment.
Currently, there is no human evidence proving that plasmalogen can clear Aβ, reverse brain atrophy, or prevent mild cognitive impairment from progressing to dementia, or reduce the incidence of Alzheimer's disease. Any product marketing involving treatment, reversal, or prevention of disease has already gone beyond existing human evidence.
Source, Content, and Product Identification
Commonly available scallop, sea squirt, and chicken breast-derived raw materials on the market are all called plasmalogen, but their specific compositions are not exactly the same. When referencing human studies, priority should be given to confirming the source, purity, and daily effective ingredients used in the study, rather than just looking at the large printed name on the product itself.
- Confirm the source:Clearly identify whether it is scallop, sea squirt, chicken breast, or other raw materials
- Confirm the actual content:A raw material amount of 34 milligrams does not equal 34 milligrams of plasmalogen; the actual effective ingredient may be only 1 milligram.
- Confirm daily dosage:Japanese cognitive human studies mainly focus on 0.5–2 mg per day, with 1 mg per day being the most common dosage in long-term studies
- Do not increase the dose on your own:Existing studies have not proven that increasing by 10 or 100 times will produce stronger effects
- Compare with target populations:Data from elderly people with cognitive decline, small healthy adult trials, and young male athletes cannot be directly applied to each other
Safety and usage boundaries
More reliable safety data comes from a large trial involving 328 people, lasting 24 weeks, with a daily dose of 1 mg, which found no safety issues between groups in terms of serious adverse events. Smaller studies in healthy adults using 0.25 or 0.5 mg daily for 12 weeks also did not observe any obvious adverse events related to the study product; In young athletes taking 2 mg daily for 4 weeks, laboratory tests and physical measurements similarly showed no significant intergroup issues.
Based on existing data, daily doses of 0.5–2 mg for several weeks to about half a year appear to be relatively safe in the short to medium term. However, current human studies mainly last 4, 12, or 24 weeks, and there is no long-term database of thousands of people taking it continuously for years. Therefore, long-term or high-dose use cannot be assumed to be absolutely safe.
- Food allergies:People with severe shellfish allergies should not consider scallop-derived products as risk-free supplements and should first confirm the ingredients and allergy information.
- People with medical conditions:If cognitive decline has already appeared, or if you are being treated for Alzheimer's disease or have multiple chronic diseases, you should discuss with your doctor first
- Medication alternatives:Supplements cannot replace standard diagnosis, prescription drugs, or doctor-arranged cognitive impairment treatment
- Effect observation:Existing long-term cognitive studies mostly last 12–24 weeks, and it is not appropriate to treat subjective changes over a few days as definitive effects
Research independence and statistical limitations
A clear shortcoming of the current evidence is insufficient independent replication. The animal mechanisms of plasmalogen derived from scallops, the large trial in 2017, the 2018 re-analysis of mild cognitive impairment, and subsequent studies on mood or concentration largely come from similar research teams; some authors have also disclosed patents related to ether phospholipids or plasmalogen preparation. Studies using sea squirts and chicken breast also involve their respective food companies. While company involvement does not render a study invalid, fully independent teams are needed to replicate experiments using the same products and pre-specified endpoints.
Multiple trials also show similar statistical patterns: the overall primary endpoints are not significant, but subgroups or individual components are significant. The primary endpoint for all 328 participants in one study was negative, with positive signals coming from female or younger patient subgroups; The total MMSE score in the mild cognitive impairment analysis was not significant, but the orientation sub-item was significant; In a study of 40 athletes, the overall mood score was not significant, but anger and fatigue sub-items were significant. These results do not indicate complete ineffectiveness, but they do reduce confidence in claims of comprehensive cognitive enhancement.
How to form reasonable expectations
The reasons why plasmalogen is noteworthy are clear: it naturally exists in brain cell membranes and is related to neural membranes and synaptic structures; a decrease in certain plasmalogens has been observed in studies related to aging and Alzheimer's disease; cell experiments involve survival signals such as Akt and ERK; animal experiments show changes in BDNF, neurogenesis, microglia, neuroinflammation, and learning and memory; human trials have also indeed observed improvements in certain memory and spatial orientation tasks.
The weakest link in the evidence is precisely also the most important step: how much, for how long, and for whom these mechanisms can translate into clinical improvements in humans. The largest randomized double-blind trials have not demonstrated an advantage in overall cognitive endpoints for the entire population, and most of the existing positive results come from small samples, subgroups, or specific items. Therefore, a more reasonable expectation before use is for mild, domain-specific changes rather than treating it as a potent cognitive enhancer.
Conclusion
Plasmalogens are a type of special ether phospholipid naturally present in human neuronal cell membranes and have a relatively complete fundamental biological research framework. In human randomized trials with daily doses of 0.5–2 milligrams for several weeks up to 24 weeks, improvements have been observed in language and visual memory, spatial orientation, and some sustained cognitive tasks, with short to medium-term safety also being relatively stable.
The boundaries of the evidence are still determined by the largest randomized double-blind trial with 328 participants over 24 weeks: for the primary and secondary overall endpoints of all subjects with mild cognitive impairment and mild Alzheimer's disease, plasmalogen did not show significant superiority over placebo. Subsequent positive results mostly come from specific subgroups, specific cognitive domains, and smaller-scale studies in healthy individuals.
At the current stage, it is suitable to be regarded as a potentially attractive cognitive health lipid with some signals from human random trials, but its efficacy consistency and independent reproducibility are still limited. It is not a confirmed treatment for mild cognitive impairment or Alzheimer's disease, nor is there evidence proving that it can prevent dementia.